Measuring [18F]FDG uptake in breast cancer during chemotherapy: Comparison of analytical methods

Nanda C. Krak, Jacobus J M Van der Hoeven, Otto S. Hoekstra, Jos W R Twisk, Elsken Van der Wall, Adriaan A. Lammertsma

Research output: Contribution to journalArticle

Abstract

Over the years several analytical methods have been proposed for the measurement of glucose metabolism using fluorine-18 fluorodeoxyglucose ([18F]FDG) and positron emission tomography (PET). The purpose of this study was to evaluate which of these (often simplified) methods could potentially be used for clinical response monitoring studies in breast cancer. Prior to chemotherapy, dynamic [18F]FDG scans were performed in 20 women with locally advanced (n=10) or metastasised (n=10) breast cancer. Additional PET scans were acquired after 8 days (n=8), and after one, three and six courses of chemotherapy (n=18, 10 and 6, respectively). Non-linear regression (NLR) with the standard two tissue compartment model was used as the gold standard for measurement of [18F]FDG uptake and was compared with the following methods: Patlak graphical analysis, simplified kinetic method (SKM), SUV-based net influx constant ("Sadato" method), standard uptake value [normalised for weight, lean body mass (LBM) and body surface area (BSA), with and without corrections for glucose (g)], tumour to non-tumour ratio (TNT), 6P model and total lesion evaluation (TLE). Correlation coefficients between each analytical method and NLR were calculated using multilevel analysis. In addition, for the most promising methods (Patlak, SKM, SUVLBMg and SUVBSAg) it was explored whether correlation with NLR changed with different time points after the start of therapy. Three methods showed excellent correlation (r>0.95) with NLR for the baseline scan: Patlak10-60 and Patlak10-45 (r=0.98 and 0.97, respectively), SKM40-60 (r=0.96) and SUVLBMg (r=0.96). Good correlation was found between NLR and SUV-based net influx constant, TLE and SUVBSAg (0.9018F]FDG uptake over time during therapy. For all methods, correlation with NLR was significantly lower for bone metastases than for other (primary or metastatic) tumour lesions (P

Original languageEnglish (US)
Pages (from-to)674-681
Number of pages8
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Volume30
Issue number5
StatePublished - May 1 2003
Externally publishedYes

Fingerprint

Breast Neoplasms
Drug Therapy
Positron-Emission Tomography
Multilevel Analysis
Glucose
Body Surface Area
Fluorodeoxyglucose F18
Neoplasms
Body Weight
Neoplasm Metastasis
Bone and Bones
Therapeutics

Keywords

  • [F]FDG
  • Breast cancer
  • Chemotherapy
  • Positron emission tomography
  • Quantitative analysis

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

Krak, N. C., Van der Hoeven, J. J. M., Hoekstra, O. S., Twisk, J. W. R., Van der Wall, E., & Lammertsma, A. A. (2003). Measuring [18F]FDG uptake in breast cancer during chemotherapy: Comparison of analytical methods. European Journal of Nuclear Medicine and Molecular Imaging, 30(5), 674-681.

Measuring [18F]FDG uptake in breast cancer during chemotherapy : Comparison of analytical methods. / Krak, Nanda C.; Van der Hoeven, Jacobus J M; Hoekstra, Otto S.; Twisk, Jos W R; Van der Wall, Elsken; Lammertsma, Adriaan A.

In: European Journal of Nuclear Medicine and Molecular Imaging, Vol. 30, No. 5, 01.05.2003, p. 674-681.

Research output: Contribution to journalArticle

Krak, NC, Van der Hoeven, JJM, Hoekstra, OS, Twisk, JWR, Van der Wall, E & Lammertsma, AA 2003, 'Measuring [18F]FDG uptake in breast cancer during chemotherapy: Comparison of analytical methods', European Journal of Nuclear Medicine and Molecular Imaging, vol. 30, no. 5, pp. 674-681.
Krak NC, Van der Hoeven JJM, Hoekstra OS, Twisk JWR, Van der Wall E, Lammertsma AA. Measuring [18F]FDG uptake in breast cancer during chemotherapy: Comparison of analytical methods. European Journal of Nuclear Medicine and Molecular Imaging. 2003 May 1;30(5):674-681.
Krak, Nanda C. ; Van der Hoeven, Jacobus J M ; Hoekstra, Otto S. ; Twisk, Jos W R ; Van der Wall, Elsken ; Lammertsma, Adriaan A. / Measuring [18F]FDG uptake in breast cancer during chemotherapy : Comparison of analytical methods. In: European Journal of Nuclear Medicine and Molecular Imaging. 2003 ; Vol. 30, No. 5. pp. 674-681.
@article{fc05e9ed842741dc879856d5cfbb9455,
title = "Measuring [18F]FDG uptake in breast cancer during chemotherapy: Comparison of analytical methods",
abstract = "Over the years several analytical methods have been proposed for the measurement of glucose metabolism using fluorine-18 fluorodeoxyglucose ([18F]FDG) and positron emission tomography (PET). The purpose of this study was to evaluate which of these (often simplified) methods could potentially be used for clinical response monitoring studies in breast cancer. Prior to chemotherapy, dynamic [18F]FDG scans were performed in 20 women with locally advanced (n=10) or metastasised (n=10) breast cancer. Additional PET scans were acquired after 8 days (n=8), and after one, three and six courses of chemotherapy (n=18, 10 and 6, respectively). Non-linear regression (NLR) with the standard two tissue compartment model was used as the gold standard for measurement of [18F]FDG uptake and was compared with the following methods: Patlak graphical analysis, simplified kinetic method (SKM), SUV-based net influx constant ({"}Sadato{"} method), standard uptake value [normalised for weight, lean body mass (LBM) and body surface area (BSA), with and without corrections for glucose (g)], tumour to non-tumour ratio (TNT), 6P model and total lesion evaluation (TLE). Correlation coefficients between each analytical method and NLR were calculated using multilevel analysis. In addition, for the most promising methods (Patlak, SKM, SUVLBMg and SUVBSAg) it was explored whether correlation with NLR changed with different time points after the start of therapy. Three methods showed excellent correlation (r>0.95) with NLR for the baseline scan: Patlak10-60 and Patlak10-45 (r=0.98 and 0.97, respectively), SKM40-60 (r=0.96) and SUVLBMg (r=0.96). Good correlation was found between NLR and SUV-based net influx constant, TLE and SUVBSAg (0.9018F]FDG uptake over time during therapy. For all methods, correlation with NLR was significantly lower for bone metastases than for other (primary or metastatic) tumour lesions (P",
keywords = "[F]FDG, Breast cancer, Chemotherapy, Positron emission tomography, Quantitative analysis",
author = "Krak, {Nanda C.} and {Van der Hoeven}, {Jacobus J M} and Hoekstra, {Otto S.} and Twisk, {Jos W R} and {Van der Wall}, Elsken and Lammertsma, {Adriaan A.}",
year = "2003",
month = "5",
day = "1",
language = "English (US)",
volume = "30",
pages = "674--681",
journal = "European Journal of Nuclear Medicine and Molecular Imaging",
issn = "1619-7070",
publisher = "Springer Verlag",
number = "5",

}

TY - JOUR

T1 - Measuring [18F]FDG uptake in breast cancer during chemotherapy

T2 - Comparison of analytical methods

AU - Krak, Nanda C.

AU - Van der Hoeven, Jacobus J M

AU - Hoekstra, Otto S.

AU - Twisk, Jos W R

AU - Van der Wall, Elsken

AU - Lammertsma, Adriaan A.

PY - 2003/5/1

Y1 - 2003/5/1

N2 - Over the years several analytical methods have been proposed for the measurement of glucose metabolism using fluorine-18 fluorodeoxyglucose ([18F]FDG) and positron emission tomography (PET). The purpose of this study was to evaluate which of these (often simplified) methods could potentially be used for clinical response monitoring studies in breast cancer. Prior to chemotherapy, dynamic [18F]FDG scans were performed in 20 women with locally advanced (n=10) or metastasised (n=10) breast cancer. Additional PET scans were acquired after 8 days (n=8), and after one, three and six courses of chemotherapy (n=18, 10 and 6, respectively). Non-linear regression (NLR) with the standard two tissue compartment model was used as the gold standard for measurement of [18F]FDG uptake and was compared with the following methods: Patlak graphical analysis, simplified kinetic method (SKM), SUV-based net influx constant ("Sadato" method), standard uptake value [normalised for weight, lean body mass (LBM) and body surface area (BSA), with and without corrections for glucose (g)], tumour to non-tumour ratio (TNT), 6P model and total lesion evaluation (TLE). Correlation coefficients between each analytical method and NLR were calculated using multilevel analysis. In addition, for the most promising methods (Patlak, SKM, SUVLBMg and SUVBSAg) it was explored whether correlation with NLR changed with different time points after the start of therapy. Three methods showed excellent correlation (r>0.95) with NLR for the baseline scan: Patlak10-60 and Patlak10-45 (r=0.98 and 0.97, respectively), SKM40-60 (r=0.96) and SUVLBMg (r=0.96). Good correlation was found between NLR and SUV-based net influx constant, TLE and SUVBSAg (0.9018F]FDG uptake over time during therapy. For all methods, correlation with NLR was significantly lower for bone metastases than for other (primary or metastatic) tumour lesions (P

AB - Over the years several analytical methods have been proposed for the measurement of glucose metabolism using fluorine-18 fluorodeoxyglucose ([18F]FDG) and positron emission tomography (PET). The purpose of this study was to evaluate which of these (often simplified) methods could potentially be used for clinical response monitoring studies in breast cancer. Prior to chemotherapy, dynamic [18F]FDG scans were performed in 20 women with locally advanced (n=10) or metastasised (n=10) breast cancer. Additional PET scans were acquired after 8 days (n=8), and after one, three and six courses of chemotherapy (n=18, 10 and 6, respectively). Non-linear regression (NLR) with the standard two tissue compartment model was used as the gold standard for measurement of [18F]FDG uptake and was compared with the following methods: Patlak graphical analysis, simplified kinetic method (SKM), SUV-based net influx constant ("Sadato" method), standard uptake value [normalised for weight, lean body mass (LBM) and body surface area (BSA), with and without corrections for glucose (g)], tumour to non-tumour ratio (TNT), 6P model and total lesion evaluation (TLE). Correlation coefficients between each analytical method and NLR were calculated using multilevel analysis. In addition, for the most promising methods (Patlak, SKM, SUVLBMg and SUVBSAg) it was explored whether correlation with NLR changed with different time points after the start of therapy. Three methods showed excellent correlation (r>0.95) with NLR for the baseline scan: Patlak10-60 and Patlak10-45 (r=0.98 and 0.97, respectively), SKM40-60 (r=0.96) and SUVLBMg (r=0.96). Good correlation was found between NLR and SUV-based net influx constant, TLE and SUVBSAg (0.9018F]FDG uptake over time during therapy. For all methods, correlation with NLR was significantly lower for bone metastases than for other (primary or metastatic) tumour lesions (P

KW - [F]FDG

KW - Breast cancer

KW - Chemotherapy

KW - Positron emission tomography

KW - Quantitative analysis

UR - http://www.scopus.com/inward/record.url?scp=0037907582&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037907582&partnerID=8YFLogxK

M3 - Article

C2 - 12640556

AN - SCOPUS:0037907582

VL - 30

SP - 674

EP - 681

JO - European Journal of Nuclear Medicine and Molecular Imaging

JF - European Journal of Nuclear Medicine and Molecular Imaging

SN - 1619-7070

IS - 5

ER -